bullish
JD Health
JD Health (6618.HK) - It's Time to Reassess the Business Prospects and Valuation
The essence of JD Health's business is “pharmaceutical e-commerce” rather than “a comprehensive online healthcare platform”. Without second growth point with certainty, high valuation is unreasonable.
Equity Bottom-Up
308 Views, 09 Mar 2023 08:55
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- Unlimited Research Summaries
- Personalised Alerts
- Custom Watchlists
- Company Analytics & News
- Events & Webinars
Trusted by:
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Ping An Healthcare and Technology Company Limited (1833.HK)- To Turn Things Around or to Fail Again?15 Mar 2023
- “Sudden Death” of Silicon Valley Bank (SVB) - The Impact on China Healthcare13 Mar 2023
- China Healthcare Weekly (Mar.10)- Three Conditions to Be Biopharma, Anticipate the Collapse, DS-820112 Mar 2023
- JD Health (6618.HK) - It's Time to Reassess the Business Prospects and Valuation09 Mar 2023
- Keymed Biosciences (2162.HK) - We Have High Hopes for Keymed, but Valuation Is Expensive21 Feb 2023
- Jacobio Pharmaceuticals Placement (1167.HK) - We Keep Hope for Jacobio Because of Dr. Wang Yinxiang13 Feb 2023
- Shanghai Haohai Biological Technology (688366.CH/6826.HK)- Disappointing Earnings and Gloomy Outlook10 Feb 2023
- JD Health (6618.HK) 2022H1 - A Second Growth Point Is Needed to Reassure Investment Logic30 Aug 2022
- Ping An Good Doctor (1833.HK) - A Vicious Cycle?30 Aug 2021
x